Oxyfedrine L-form HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596453

CAS#: 16777-42-7

Description: Oxyfedrine L-form HCl is a drug used in the treatment of angina pectoris, heart failure, conduction defects, and myocardial infarction. It is a partial agonist at beta adrenergic receptors and acts as a coronary vasodilator and cardiotonic agent.

Chemical Structure

Oxyfedrine L-form HCl
CAS# 16777-42-7

Theoretical Analysis

MedKoo Cat#: 596453
Name: Oxyfedrine L-form HCl
CAS#: 16777-42-7
Chemical Formula: C19H24ClNO3
Exact Mass:
Molecular Weight: 349.85
Elemental Analysis: C, 65.23; H, 6.91; Cl, 10.13; N, 4.00; O, 13.72

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Oxyfedrine L-form hydrochloride; Ildamen; D563; D 563; D-563; Modacor; Oxyfedrin; FDA 1576; L-Oxyfedrine hydrochloride;

IUPAC/Chemical Name: 3-((1-hydroxy-1-phenylpropan-2-yl)amino)-1-(3-methoxyphenyl)propan-1-one hydrochloride


InChi Code: InChI=1S/C19H23NO3.ClH/c1-14(19(22)15-7-4-3-5-8-15)20-12-11-18(21)16-9-6-10-17(13-16)23-2;/h3-10,13-14,19-20,22H,11-12H2,1-2H3;1H


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 349.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Hayat S, Khalique G, Irfan M, Wani AS, Tripathi BN, Ahmad A. Physiological changes induced by chromium stress in plants: an overview. Protoplasma. 2012 Jul;249(3):599-611. doi: 10.1007/s00709-011-0331-0. Epub 2011 Oct 16. Review. PubMed PMID: 22002742.

2: Mazumdar K, Asok Kumar K, Dutta NK. Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: scope and hope for the future. Int J Antimicrob Agents. 2010 Oct;36(4):295-302. doi: 10.1016/j.ijantimicag.2010.05.003. Epub 2010 Jun 29. Review. PubMed PMID: 20591629.

3: Sukoyan GV, Antelava NA. Rational drug correction of systemic inflammatory response syndrome in severe experimental heart failure. Bull Exp Biol Med. 2009 Apr;147(4):411-4. English, Russian. PubMed PMID: 19704936.

4: Mazumdar K, Dutta NK, Kumar KA, Dastidar SG. In vitro and in vivo synergism between tetracycline and the cardiovascular agent oxyfedrine HCl against common bacterial strains. Biol Pharm Bull. 2005 Apr;28(4):713-7. PubMed PMID: 15802815.

5: Dzhanashiya PKh, Vladytskaya OV, Salibegashvili NV. Efficiency and mechanisms of the antioxidant effect of standard therapy and refracterin in the treatment of chronic heart failure in elderly patients with postinfarction cardiosclerosis. Bull Exp Biol Med. 2004 Oct;138(4):412-4. PubMed PMID: 15665959.

6: Kanorskii SG, Galenko-Yaroshevskii PA, Zingilevskii KB. Efficiency of refracterin in patients with chronic cardiac insufficiency caused by coronary heart disease. Bull Exp Biol Med. 2004 Jul;138(1):67-9. PubMed PMID: 15514727.

7: Mazumdar K, Ganguly K, Kumar KA, Dutta NK, Chakrabarty AN, Dastidar SG. Antimicrobial potentiality of a new non-antibiotic: the cardiovascular drug oxyfedrine hydrochloride. Microbiol Res. 2003;158(3):259-64. PubMed PMID: 14521236.

8: Karsanov NV, Sukoian GV, Dzhibgashvili IK, Tatulashvili DR, Gorelishvili II, Guchua EI. [The subcellular pathophysiology of heart failure due to toxic-allergic myocarditis and the action of refracterin on intracardiac hemodynamics and the functional state of the 3 subcellular cardiomyocyte systems responsible for the act of contraction-relaxation]. Patol Fiziol Eksp Ter. 1999 Jul-Sep;(3):3-8. Russian. PubMed PMID: 10498985.

9: Zwicker K, Damerau W, Dikalov S, Scholtyssek H, Schimke I, Zimmer G. Superoxide radical scavenging by phenolic bronchodilators under aprotic and aqueous conditions. Biochem Pharmacol. 1998 Aug 1;56(3):301-5. PubMed PMID: 9744566.

10: Paleev NR, Sanina NP, Paleev FN, Pronina VP, Sukoian GV, Karsanov NV. [Chronic cardiac failure in noncoronarogenic myocardial diseases and refracterin effects]. Klin Med (Mosk). 1998;76(6):21-6. Russian. PubMed PMID: 9693495.

11: Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet. 1998 Jul;35(1):9-36. Review. PubMed PMID: 9673832.

12: Maulik SK, Seth SD, Maulik M, Manchanda SC. Oxyfedrine in myocardial stunning. Indian J Exp Biol. 1997 Nov;35(11):1214-7. PubMed PMID: 9567753.

13: Qu YZ, Wang YE, Li XX. Effects of thiofedrine on platelet aggregation, thromboxane B2 and 6-keto-PGF1 alpha in rats. Methods Find Exp Clin Pharmacol. 1996 Jun;18(5):297-300. PubMed PMID: 8817463.

14: Wetzelsberger N, Birkel M, Fuder H, Lücker PW, Stiegler S, Scheithauer S, Thümmler D. Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions. Methods Find Exp Clin Pharmacol. 1995 Apr;17(3):185-91. PubMed PMID: 8531509.

15: Qu YZ, Li XX. Influence of thiofedrine on platelet aggregation, intraplatelet cyclic cAMP and malondialdehyde in rats. Methods Find Exp Clin Pharmacol. 1994 May;16(4):253-6. PubMed PMID: 8051984.

16: Yu J, Li XX. [Effects of oxyfedrine on high blood viscosity and myocardial necrosis induced by epinephrine and ice water stress in rats]. Zhongguo Yao Li Xue Bao. 1993 Jul;14(4):364-6. Chinese. PubMed PMID: 8249637.

17: Kaski JC, Araujo L, Maseri A. Effects of oxyfedrine on regional myocardial blood flow in patients with coronary artery disease. Cardiovasc Drugs Ther. 1991 Dec;5(6):991-6. PubMed PMID: 1801897.

18: Lantzsch W, Fikentscher R, Obrebowski A. [Ageusia as the aftereffect of oxyfedrine use]. Otolaryngol Pol. 1991;45(2):148-50. Polish. PubMed PMID: 2067860.

19: Alexander T, Krishnaswami S. Effect of intravenous oxyfedrine on exercise in patients with ischaemic heart disease. Indian Heart J. 1991 Jan-Feb;43(1):21-4. PubMed PMID: 1894296.

20: Gavrisiuk VK, Morskaia ND, Iachnik AI, Morozova NA, Iakhnitsia TV. [Use of beta 1-adrenostimulants in circulatory failure in patients with chronic inflammatory lung diseases]. Kardiologiia. 1990 Mar;30(3):32-5. Russian. PubMed PMID: 2199719.